Back to Screener

Healthcare

UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF(CBUS)

Live Price

Offline

$1.34

-2.19% today

1Y Change

-11.04%

Window

Jun 26, 2025 โ†’ Jun 24, 2026

Market Cap
$70.00M
Revenue Growth
-14.6%
EPS Growth
+74.3%
Dividend Yield
0.0%

Coverage: 249 bars ยท Jun 26, 2025 โ†’ Jun 24, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF (CBUS) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $1.34 and down 11.0% across the available one-year price window (Jun 26, 2025 โ†’ Jun 24, 2026). Baseline metrics include revenue growth of -14.6%, EPS growth of +74.3%, a dividend yield of 0.0%. What stands out right now is revenue -14.6%, EPS +74.3%, free cash flow +13.1% with operating margin -2429.6% and ROIC -30.3%. Valuation already assumes a fairly strong business story at price/sales 19.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CBUS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

CBUS vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

CBUS

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

CBUS Max Drawdown

-70.37%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CBUS and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for CBUS

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.